CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.75B, above the global median of $1.18B
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.53BEUR1.75B · vs all stocks (USD)
Revenue (TTM)
32.59MEUR37.16M · vs all stocks (USD)
Profit Margin
-73.52%vs Biotechnology peers
Beta
0.5660xvs all stocks
52-Week Change
147.78%vs all stocks
Market Capitalization
1.53BEUR1.75B · vs all stocks (USD)
Enterprise Value
1.48BEUR1.68B · vs all stocks (USD)
Forward P/E
-124.88xvs Biotechnology peers
Price to Sales (TTM)
46.24xvs Biotechnology peers
Enterprise to Revenue
45.34xvs Biotechnology peers
Enterprise to EBITDA
-140.89xvs Biotechnology peers
Profit Margin
-73.52%vs Biotechnology peers
Operating Margin
-196.42%vs Biotechnology peers
Return on Assets (TTM)
-10.06%vs Biotechnology peers
Revenue (TTM)
32.59MEUR37.16M · vs all stocks (USD)
Revenue per Share (TTM)
0.6820EURUpdated Sep 23, 2026Gross Profit (TTM)
32.59MEUR37.16M · vs all stocks (USD)
EBITDA (TTM)
-10.49MEUR-11.96M · vs all stocks (USD)
Net Income (TTM)
-23.96MEUR-27.32M · vs all stocks (USD)
Operating Cash Flow (TTM)
-33.42MEUR-38.11M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-7.89MEUR-9.00M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00EURUpdated Sep 23, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
29.64MEURFY2025 · Dec 31, 2025Operating Income
-10.82MEUR-12.33M · vs all stocks (USD)
Pre-tax Income
-23.96MEURFY2025 · Dec 31, 2025Income Tax Expense
3.00KEURFY2025 · Dec 31, 2025Net Income
-23.96MEURFY2025 · Dec 31, 2025EBIT
-13.56MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
-8.83MEURFY2025 · Dec 31, 2025Research & Development
23.11MEURFY2025 · Dec 31, 2025Selling, General & Administrative
20.22MEURFY2025 · Dec 31, 2025Other Operating Expenses
-404.00KEURFY2025 · Dec 31, 2025Non-operating Interest Income
985.00KEURFY2025 · Dec 31, 2025Non-operating Interest Expense
10.39MEURFY2025 · Dec 31, 2025Net Income from Continuing Operations
-23.96MEURFY2025 · Dec 31, 2025Operating Cash Flow
-27.74MEURFY2025 · Dec 31, 2025Free Cash Flow
-28.28MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
52.75MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-23.96MEURFY2025 · Dec 31, 2025Depreciation & Amortization
1.50MEURFY2025 · Dec 31, 2025Deferred Taxes (CF)
3.00KEURFY2025 · Dec 31, 2025Stock-based Compensation
3.54MEURFY2025 · Dec 31, 2025Other Non-cash Items
-10.83MEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.85MEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
159.00KEURFY2025 · Dec 31, 2025Capital Expenditures
-538.00KEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-8.00KEURFY2025 · Dec 31, 2025Net Investing Cash Flow
-538.00KEURFY2025 · Dec 31, 2025Long-term Debt Issuance
42.93MEURFY2025 · Dec 31, 2025Long-term Debt Payments
-4.74MEURFY2025 · Dec 31, 2025Common Dividends Paid
0.00EURFY2025 · Dec 31, 2025Other Financing Charges
-778.00KEURFY2025 · Dec 31, 2025Net Financing Cash Flow
38.95MEURFY2025 · Dec 31, 2025Shares Outstanding
48.39MSharesUpdated Sep 23, 2026Float Shares
33.88MSharesUpdated Sep 23, 2026% Held by Insiders
15.55%vs all stocks
% Held by Institutions
33.39%vs all stocks
Total Cash (MRQ)
52.75MEUR60.14M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.09EURUpdated Sep 23, 2026Total Debt (MRQ)
95.32MEUR108.68M · vs all stocks (USD)
Current Ratio (MRQ)
1.09xvs Biotechnology peers
Book Value per Share (MRQ)
-1.75EURUpdated Sep 23, 2026Total Assets
67.76MEUR77.26M · vs all stocks (USD)
Total Current Assets
62.75MEURFY2025 · Dec 31, 2025Total Liabilities
152.24MEURFY2025 · Dec 31, 2025Total Non-current Assets
5.01MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
94.74MEURFY2025 · Dec 31, 2025Total Current Liabilities
57.51MEURFY2025 · Dec 31, 2025Cash
810.00KEURFY2025 · Dec 31, 2025Cash Equivalents
51.94MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
52.75MEURFY2025 · Dec 31, 2025Accounts Receivable
2.14MEURFY2025 · Dec 31, 2025Accounts Payable
6.58MEURFY2025 · Dec 31, 2025Short-term Debt
4.31MEURFY2025 · Dec 31, 2025Deferred Revenue
36.22MEURFY2025 · Dec 31, 2025Other Current Liabilities
312.00KEURFY2025 · Dec 31, 2025Long-term Debt
91.01MEURFY2025 · Dec 31, 2025Other Non-current Liabilities
3.22MEURFY2025 · Dec 31, 2025Common Stock (Book)
1.45MEURFY2025 · Dec 31, 2025Retained Earnings
-23.96MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
-84.48MEUR-96.32M · vs all stocks (USD)
Treasury Stock
228.00KEURFY2025 · Dec 31, 202552-Week Low
11.76EURUpdated Sep 23, 202652-Week High
47.66EURUpdated Sep 23, 202652-Week Change
147.78%vs all stocks
Beta
0.5660xvs all stocks
50-Day MA
33.81EURUpdated Sep 23, 2026200-Day MA
28.42EURUpdated Sep 23, 2026Avg 10-Day Volume
138.27KSharesUpdated Sep 23, 2026Avg 30-Day Volume
158.98KSharesUpdated Sep 23, 2026Diluted EPS (TTM)
-0.5000EURUpdated Sep 23, 2026Other Income / Expense
-3.23MEURFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.75B, above the global median of $1.18BNotable
Market cap (USD): 1,749,547,780.682Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Hanall Biopharma Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventisbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jubilant Pharmova Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Novavax Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Chipscreen Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Septarna Inc.
Tier 1ProductionApproval-Gated PipelineRule
4DMedical Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Alivus Life Sciences Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
PolyPeptide Group AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tibet Rhodiola Pharmaceutical Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule